Overcoming drug resistance in ovarian cancer using the Fanconi Anemia pathway
Targeting Fanconi Anemia pathway to overcome platinum drug resistance in ovarian cancer
This study is looking at how to make chemotherapy work better for ovarian cancer patients by understanding a specific pathway in cancer cells that can make them resistant to treatment, with the hope of finding new ways to improve their care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | George Washington University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project ID | NIH-11059114 on NIH RePORTER |
What this research studies
This research investigates how the Fanconi Anemia (FA) pathway can be targeted to combat resistance to platinum-based chemotherapy in ovarian cancer patients. The study aims to understand the mechanisms that lead to the activation of FA signaling in cancer cells, which is a major contributor to treatment failure. By exploring the role of specific proteins involved in this pathway, the researchers hope to develop new strategies that enhance the effectiveness of existing therapies. Patients may benefit from insights that could lead to improved treatment options and outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with ovarian cancer who have shown resistance to platinum-based chemotherapy.
Not a fit: Patients with ovarian cancer who have not undergone platinum-based chemotherapy or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new therapeutic strategies to improve the effectiveness of chemotherapy for ovarian cancer patients who currently experience drug resistance.
How similar studies have performed: Previous research has shown promising results in targeting the FA pathway to overcome drug resistance in various cancers, indicating that this approach has potential for success.
Where this research is happening
Washington, United States
- George Washington University — Washington, United States (Active)
Researchers
- Principal investigator: Zhu, Wenge — George Washington University
- Study coordinator: Zhu, Wenge
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.